Clinical Trial Update: Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating neoadjuvant followed by adjuvant pembrolizumab in patients with resectable advanced basal cell carcinoma of the head and neck has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma of the Head and Neck

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Basal Cell Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED